poisar

Stocks · News reference

AstraZeneca Announces That Results From Its CLARITY-Gastric01 Global Phase III Trial Showed That Sonesitatug Vedotin Demonstrated Statistically Significant And Highly Clinically Meaningful Improvement In Overall Survival

Jul 27, 2026, 11:13 AMBenzinga Newsdesk

Results in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZN
Source
benzinga
Observed
Jul 27, 2026, 11:13 AM
Checked
Jul 27, 2026, 11:13 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK